{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:37:09Z","timestamp":1785854229012,"version":"3.56.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Community-acquired respiratory viruses (CARV), such as influenza-, parainfluenza- or respiratory syncytial virus, pose a significant threat to immunocompromised patients with cancer. Following the COVID-19 pandemic, SARS-CoV-2 has now joined the ranks of endemic respiratory viruses and continues to be a cause of significant morbidity and mortality in patients with cancer. Strategies to protect this vulnerable patient population both by prevention of infection and by early therapeutic intervention in case of infectious disease are therefore of utmost importance. This guideline provides updated evidence-based recommendations on diagnosis, prophylaxis and treatment of CARV infections including COVID-19 in patients with solid tumors or hematologic malignancies to support clinicians in offering optimal care. The guideline is based on a systematic review of currently available data and was developed until the beginning of 2025 by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).<\/jats:p>","DOI":"10.1007\/s00277-026-06769-9","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:21:18Z","timestamp":1768969278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevention, diagnosis and management of community acquired respiratory virus infections including COVID-19 in patients with cancer: 2025 updated evidence-based guideline of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO)"],"prefix":"10.1007","volume":"105","author":[{"given":"Nicola","family":"Giesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Khatamzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Korell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hentrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Henze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Peter","family":"Heu\u00dfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn-Erik Ole","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte B.","family":"Monin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Voigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"25","key":"6769_CR1","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","volume":"344","author":"CB Hall","year":"2001","unstructured":"Hall CB (2001) Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344(25):1917\u20131928. https:\/\/doi.org\/10.1056\/NEJM200106213442507","journal-title":"N Engl J Med"},{"issue":"9","key":"6769_CR2","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1086\/425004","volume":"39","author":"WG Nichols","year":"2004","unstructured":"Nichols WG et al (2004) Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39(9):1300\u20131306. https:\/\/doi.org\/10.1086\/425004","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6769_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood.v98.3.573","volume":"98","author":"WG Nichols","year":"2001","unstructured":"Nichols WG et al (2001) Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98(3):573\u2013578. https:\/\/doi.org\/10.1182\/blood.v98.3.573","journal-title":"Blood"},{"issue":"194","key":"6769_CR4","doi-asserted-by":"publisher","first-page":"20220477","DOI":"10.1098\/rsif.2022.0477","volume":"19","author":"ANM Kraay","year":"2022","unstructured":"Kraay ANM et al (2022) The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2. J R Soc Interface 19(194):20220477. https:\/\/doi.org\/10.1098\/rsif.2022.0477","journal-title":"J R Soc Interface"},{"issue":"1","key":"6769_CR5","doi-asserted-by":"publisher","first-page":"12511","DOI":"10.1038\/s41598-023-38869-1","volume":"13","author":"C Geismar","year":"2023","unstructured":"Geismar C et al (2023) Symptom profiles of community cases infected by influenza, RSV, rhinovirus, seasonal coronavirus, and SARS-CoV-2 variants of concern. Sci Rep 13(1):12511. https:\/\/doi.org\/10.1038\/s41598-023-38869-1","journal-title":"Sci Rep"},{"key":"6769_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ejca.2016.08.015","volume":"67","author":"M von Lilienfeld-Toal","year":"2016","unstructured":"von Lilienfeld-Toal M et al (2016) Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the infectious diseases working party of the German society for haematology and medical oncology. Eur J Cancer 67:200\u2013212. https:\/\/doi.org\/10.1016\/j.ejca.2016.08.015","journal-title":"Eur J Cancer"},{"key":"6769_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejca.2022.11.030","volume":"181","author":"N Giesen","year":"2023","unstructured":"Giesen N et al (2023) AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, Pharmacological prophylaxis and therapy in light of the Omicron variants. Eur J Cancer 181:102\u2013118. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.030","journal-title":"Eur J Cancer"},{"key":"6769_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2021.01.033","volume":"147","author":"N Giesen","year":"2021","unstructured":"Giesen N et al (2021) 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer 147:154\u2013160. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.033","journal-title":"Eur J Cancer"},{"key":"6769_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejca.2020.09.009","volume":"140","author":"N Giesen","year":"2020","unstructured":"Giesen N et al (2020) Evidence-based management of COVID-19 in cancer patients: guideline by the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO). Eur J Cancer 140:86\u2013104. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.009","journal-title":"Eur J Cancer"},{"issue":"Suppl 7","key":"6769_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1469-0691.12041","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after Haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl 7):53\u201367. https:\/\/doi.org\/10.1111\/1469-0691.12041","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"6769_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L et al (2021) COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol 14(1):168. https:\/\/doi.org\/10.1186\/s13045-021-01177-0","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6769_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00277-020-04328-4","volume":"100","author":"MM Ruthrich","year":"2021","unstructured":"Ruthrich MM et al (2021) COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 100(2):383\u2013393. https:\/\/doi.org\/10.1007\/s00277-020-04328-4","journal-title":"Ann Hematol"},{"issue":"14","key":"6769_CR13","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","volume":"386","author":"SA Madhi","year":"2022","unstructured":"Madhi SA et al (2022) Population immunity and Covid-19 severity with Omicron variant in South Africa. N Engl J Med 386(14):1314\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa2119658","journal-title":"N Engl J Med"},{"key":"6769_CR14","doi-asserted-by":"publisher","first-page":"n3151","DOI":"10.1136\/bmj.n3151","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase E (2021) Covid-19: hospital admission 50\u201370% less likely with Omicron than delta, but transmission a major concern. BMJ 375:n3151. https:\/\/doi.org\/10.1136\/bmj.n3151","journal-title":"BMJ"},{"issue":"7","key":"6769_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1470-2045(22)00273-X","volume":"23","author":"DJ Pinato","year":"2022","unstructured":"Pinato DJ et al (2022) Outcomes of the SARS-CoV-2 Omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncol 23(7):865\u2013875. https:\/\/doi.org\/10.1016\/S1470-2045(22)00273-X","journal-title":"Lancet Oncol"},{"issue":"6","key":"6769_CR16","doi-asserted-by":"publisher","first-page":"106347","DOI":"10.1016\/j.jinf.2024.106347","volume":"89","author":"F Farina","year":"2024","unstructured":"Farina F et al (2024) Impact of respiratory syncytial virus (RSV) on adult haematology oncology patients. J Infect 89(6):106347. https:\/\/doi.org\/10.1016\/j.jinf.2024.106347","journal-title":"J Infect"},{"issue":"1","key":"6769_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/jmv.24930","volume":"90","author":"D Vilar-Compte","year":"2018","unstructured":"Vilar-Compte D et al (2018) Influenza in patients with hematological malignancies: experience at two comprehensive cancer centers. J Med Virol 90(1):50\u201360. https:\/\/doi.org\/10.1002\/jmv.24930","journal-title":"J Med Virol"},{"issue":"10241","key":"6769_CR18","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer NM et al (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395(10241):1907\u20131918. https:\/\/doi.org\/10.1016\/S0140-6736(20)31187-9","journal-title":"Lancet"},{"issue":"7","key":"6769_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","volume":"10","author":"V Mehta","year":"2020","unstructured":"Mehta V et al (2020) Case fatality rate of cancer patients with COVID-19 in a new York hospital system. Cancer Discov 10(7):935\u2013941. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0516","journal-title":"Cancer Discov"},{"issue":"7821","key":"6769_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ et al (2020) Factors associated with COVID-19-related death using opensafely. Nature 584(7821):430\u2013436. https:\/\/doi.org\/10.1038\/s41586-020-2521-4","journal-title":"Nature"},{"issue":"6","key":"6769_CR21","doi-asserted-by":"publisher","first-page":"e12994","DOI":"10.1111\/tid.12994","volume":"20","author":"E Vakil","year":"2018","unstructured":"Vakil E et al (2018) Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. Transpl Infect Dis 20(6):e12994. https:\/\/doi.org\/10.1111\/tid.12994","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"6769_CR22","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/jac\/dkt111","volume":"68","author":"DP Shah","year":"2013","unstructured":"Shah DP et al (2013) Impact of aerosolized ribavirin on mortality in 280 allogeneic Haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 68(8):1872\u20131880. https:\/\/doi.org\/10.1093\/jac\/dkt111","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"6769_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/bmt.2013.94","volume":"48","author":"N Lehners","year":"2013","unstructured":"Lehners N et al (2013) Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transpl 48(12):1548\u20131553. https:\/\/doi.org\/10.1038\/bmt.2013.94","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"6769_CR24","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s15010-024-02213-0","volume":"52","author":"A Perez","year":"2024","unstructured":"Perez A et al (2024) Outcome of human parainfluenza virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy. Infection 52(5):1941\u20131952. https:\/\/doi.org\/10.1007\/s15010-024-02213-0","journal-title":"Infection"},{"issue":"9","key":"6769_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S2213-2600(24)00151-6","volume":"12","author":"S Feys","year":"2024","unstructured":"Feys S et al (2024) Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients. Lancet Respir Med 12(9):728\u2013742. https:\/\/doi.org\/10.1016\/S2213-2600(24)00151-6","journal-title":"Lancet Respir Med"},{"issue":"10","key":"6769_CR26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.bbmt.2012.04.012","volume":"18","author":"C Ustun","year":"2012","unstructured":"Ustun C et al (2012) Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time. Biol Blood Marrow Transpl 18(10):1580\u20131588. https:\/\/doi.org\/10.1016\/j.bbmt.2012.04.012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"6769_CR27","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.chest.2023.07.4222","volume":"164","author":"A Maillard","year":"2023","unstructured":"Maillard A et al (2023) Multiplex polymerase chain reaction assay to detect nasopharyngeal viruses in immunocompromised patients with acute respiratory failure. Chest 164(6):1364\u20131377. https:\/\/doi.org\/10.1016\/j.chest.2023.07.4222","journal-title":"Chest"},{"issue":"2","key":"6769_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/infdis\/jiad012","volume":"228","author":"C Onwuchekwa","year":"2023","unstructured":"Onwuchekwa C et al (2023) Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: A systematic literature review and Meta-analysis. J Infect Dis 228(2):173\u2013184. https:\/\/doi.org\/10.1093\/infdis\/jiad012","journal-title":"J Infect Dis"},{"issue":"9","key":"6769_CR29","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1128\/JCM.01209-08","volume":"46","author":"RY Sung","year":"2008","unstructured":"Sung RY et al (2008) Comparative study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection. J Clin Microbiol 46(9):3073\u20133076. https:\/\/doi.org\/10.1128\/JCM.01209-08","journal-title":"J Clin Microbiol"},{"key":"6769_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10111515","author":"MF Flynn","year":"2021","unstructured":"Flynn MF, Kelly M, Dooley JSG (2021) Nasopharyngeal swabs vs. nasal aspirates for respiratory virus detection: a systematic review. Pathogens. https:\/\/doi.org\/10.3390\/pathogens10111515","journal-title":"Pathogens"},{"issue":"2","key":"6769_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/sj.bmt.1704534","volume":"34","author":"CM Machado","year":"2004","unstructured":"Machado CM et al (2004) Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transpl 34(2):111\u2013114. https:\/\/doi.org\/10.1038\/sj.bmt.1704534","journal-title":"Bone Marrow Transpl"},{"issue":"Suppl 5","key":"6769_CR32","doi-asserted-by":"publisher","first-page":"S344","DOI":"10.1093\/cid\/ciu623","volume":"59","author":"RF Chemaly","year":"2014","unstructured":"Chemaly RF, Shah DP, Boeckh MJ (2014) Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 59(Suppl 5):S344\u2013S351. https:\/\/doi.org\/10.1093\/cid\/ciu623","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6769_CR33","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2010-08-263400","volume":"117","author":"JN Shah","year":"2011","unstructured":"Shah JN, Chemaly RF (2011) Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 117(10):2755\u20132763. https:\/\/doi.org\/10.1182\/blood-2010-08-263400","journal-title":"Blood"},{"key":"6769_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12729","author":"JL Pinana","year":"2017","unstructured":"Pinana JL et al (2017) A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: a pilot study. Transpl Infect Dis. https:\/\/doi.org\/10.1111\/tid.12729","journal-title":"Transpl Infect Dis"},{"key":"6769_CR35","doi-asserted-by":"publisher","first-page":"102553","DOI":"10.1016\/j.eclinm.2024.102553","volume":"71","author":"J Salmanton-Garcia","year":"2024","unstructured":"Salmanton-Garcia J et al (2024) Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine 71:102553. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102553","journal-title":"EClinicalMedicine"},{"issue":"8","key":"6769_CR36","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41409-024-02304-4","volume":"59","author":"A Perez","year":"2024","unstructured":"Perez A et al (2024) Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease. Bone Marrow Transpl 59(8):1118\u20131126. https:\/\/doi.org\/10.1038\/s41409-024-02304-4","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"6769_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cmi.2021.09.025","volume":"28","author":"E Gentilotti","year":"2022","unstructured":"Gentilotti E et al (2022) Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis. Clin Microbiol Infect 28(1):13\u201322. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.025","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"6769_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12916-022-02603-x","volume":"20","author":"E Schuit","year":"2022","unstructured":"Schuit E et al (2022) Head-to-head comparison of the accuracy of saliva and nasal rapid antigen SARS-CoV-2 self-testing: cross-sectional study. BMC Med 20(1):406. https:\/\/doi.org\/10.1186\/s12916-022-02603-x","journal-title":"BMC Med"},{"issue":"7","key":"6769_CR39","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1002\/cam4.5537","volume":"12","author":"M Caccese","year":"2023","unstructured":"Caccese M et al (2023) Antigen rapid diagnostic test monitoring for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients: is it cost-effective? Cancer Med 12(7):7795\u20137800. https:\/\/doi.org\/10.1002\/cam4.5537","journal-title":"Cancer Med"},{"issue":"11","key":"6769_CR40","doi-asserted-by":"publisher","first-page":"e29228","DOI":"10.1002\/jmv.29228","volume":"95","author":"SW Kang","year":"2023","unstructured":"Kang SW et al (2023) Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID-19: A prospective cohort study. J Med Virol 95(11):e29228. https:\/\/doi.org\/10.1002\/jmv.29228","journal-title":"J Med Virol"},{"issue":"5","key":"6769_CR41","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10096-024-04788-w","volume":"43","author":"A Maldonado-Barrueco","year":"2024","unstructured":"Maldonado-Barrueco A et al (2024) Evaluation of CLINITEST(R) rapid Covid-19\u2009+\u2009Influenza antigen test in a cohort of symptomatic patients in an emergency department. Eur J Clin Microbiol Infect Dis 43(5):853\u2013861. https:\/\/doi.org\/10.1007\/s10096-024-04788-w","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5\u20136","key":"6769_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/10408363.2011.640976","volume":"48","author":"JB Mahony","year":"2011","unstructured":"Mahony JB, Petrich A, Smieja M (2011) Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci 48(5\u20136):217\u201349. https:\/\/doi.org\/10.3109\/10408363.2011.640976","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"1","key":"6769_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccm.2016.11.004","volume":"38","author":"GW Waterer","year":"2017","unstructured":"Waterer GW (2017) Diagnosing viral and atypical pathogens in the setting of community-acquired pneumonia. Clin Chest Med 38(1):21\u201328. https:\/\/doi.org\/10.1016\/j.ccm.2016.11.004","journal-title":"Clin Chest Med"},{"issue":"3","key":"6769_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ajh.27565","volume":"100","author":"J Salmanton-Garcia","year":"2025","unstructured":"Salmanton-Garcia J et al (2025) Respiratory viruses in patients with hematological malignancy in boreal Autumn\/Winter 2023\u20132024: EPICOVIDEHA-EPIFLUEHA report. Am J Hematol 100(3):358\u2013374. https:\/\/doi.org\/10.1002\/ajh.27565","journal-title":"Am J Hematol"},{"issue":"2","key":"6769_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/cid\/cis844","volume":"56","author":"HH Hirsch","year":"2013","unstructured":"Hirsch HH et al (2013) Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 56(2):258\u201366. https:\/\/doi.org\/10.1093\/cid\/cis844","journal-title":"Clin Infect Dis"},{"issue":"2","key":"6769_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/cid\/civ272","volume":"61","author":"AP Campbell","year":"2015","unstructured":"Campbell AP et al (2015) Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis 61(2):192\u2013202. https:\/\/doi.org\/10.1093\/cid\/civ272","journal-title":"Clin Infect Dis"},{"issue":"18","key":"6769_CR47","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1182\/bloodadvances.2021004915","volume":"6","author":"YJ Kim","year":"2022","unstructured":"Kim YJ et al (2022) Respiratory viruses in hematopoietic cell transplant candidates: impact of preexisting lower tract disease on outcomes. Blood Adv 6(18):5307\u20135316. https:\/\/doi.org\/10.1182\/bloodadvances.2021004915","journal-title":"Blood Adv"},{"issue":"2","key":"6769_CR48","doi-asserted-by":"publisher","first-page":"e0148258","DOI":"10.1371\/journal.pone.0148258","volume":"11","author":"N Lehners","year":"2016","unstructured":"Lehners N et al (2016) Long-Term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PLoS ONE 11(2):e0148258. https:\/\/doi.org\/10.1371\/journal.pone.0148258","journal-title":"PLoS ONE"},{"issue":"3","key":"6769_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/infdis\/jiaa311","volume":"222","author":"S Hao","year":"2020","unstructured":"Hao S et al (2020) Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: A Case-Control study. J Infect Dis 222(3):367\u2013371. https:\/\/doi.org\/10.1093\/infdis\/jiaa311","journal-title":"J Infect Dis"},{"issue":"15","key":"6769_CR50","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/cid\/ciaa351","volume":"71","author":"K Xu","year":"2020","unstructured":"Xu K et al (2020) Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis 71(15):799\u2013806. https:\/\/doi.org\/10.1093\/cid\/ciaa351","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6769_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1128\/JCM.02151-12","volume":"51","author":"S Geis","year":"2013","unstructured":"Geis S et al (2013) Molecular characterization of a respiratory syncytial virus outbreak in a hematology unit in Heidelberg, Germany. J Clin Microbiol 51(1):155\u2013162. https:\/\/doi.org\/10.1128\/JCM.02151-12","journal-title":"J Clin Microbiol"},{"issue":"26","key":"6769_CR52","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","volume":"383","author":"T Aydillo","year":"2020","unstructured":"Aydillo T et al (2020) Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 383(26):2586\u20132588. https:\/\/doi.org\/10.1056\/NEJMc2031670","journal-title":"N Engl J Med"},{"issue":"23","key":"6769_CR53","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B et al (2020) Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 383(23):2291\u20132293. https:\/\/doi.org\/10.1056\/NEJMc2031364","journal-title":"N Engl J Med"},{"issue":"7","key":"6769_CR54","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","volume":"183","author":"VA Avanzato","year":"2020","unstructured":"Avanzato VA et al (2020) Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183(7):1901\u20131912 e9. https:\/\/doi.org\/10.1016\/j.cell.2020.10.049","journal-title":"Cell"},{"issue":"1","key":"6769_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/MCC.0000000000000906","volume":"28","author":"L Di Meglio","year":"2022","unstructured":"Di Meglio L et al (2022) Chest imaging in patients with acute respiratory failure because of coronavirus disease 2019. Curr Opin Crit Care 28(1):17\u201324. https:\/\/doi.org\/10.1097\/MCC.0000000000000906","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"6769_CR56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1148\/radiol.11092149","volume":"260","author":"T Franquet","year":"2011","unstructured":"Franquet T (2011) Imaging of pulmonary viral pneumonia. Radiology 260(1):18\u201339. https:\/\/doi.org\/10.1148\/radiol.11092149","journal-title":"Radiology"},{"key":"6769_CR57","doi-asserted-by":"publisher","first-page":"108988","DOI":"10.1016\/j.ejrad.2020.108988","volume":"128","author":"LA Marinari","year":"2020","unstructured":"Marinari LA et al (2020) Lower respiratory tract infection with human metapneumovirus: chest CT imaging features and comparison with other viruses. Eur J Radiol 128:108988. https:\/\/doi.org\/10.1016\/j.ejrad.2020.108988","journal-title":"Eur J Radiol"},{"issue":"2","key":"6769_CR58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00330-003-1985-6","volume":"14","author":"CP Heussel","year":"2004","unstructured":"Heussel CP, Kauczor HU, Ullmann AJ (2004) Pneumonia in neutropenic patients. Eur Radiol 14(2):256\u2013271. https:\/\/doi.org\/10.1007\/s00330-003-1985-6","journal-title":"Eur Radiol"},{"key":"6769_CR59","doi-asserted-by":"publisher","unstructured":"Kim EA et al (2002) Viral pneumonias in adults: radiologic and pathologic findings. Radiographics, 22 Spec No: pp. S137-49 https:\/\/doi.org\/10.1148\/radiographics.22.suppl_1.g02oc15s137","DOI":"10.1148\/radiographics.22.suppl_1.g02oc15s137"},{"issue":"7","key":"6769_CR60","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0033-1356353","volume":"186","author":"JL Mayer","year":"2014","unstructured":"Mayer JL et al (2014) CT-morphological characterization of respiratory syncytial virus (RSV) pneumonia in immune-compromised adults. Rofo 186(7):686\u2013692. https:\/\/doi.org\/10.1055\/s-0033-1356353","journal-title":"Rofo"},{"issue":"4","key":"6769_CR61","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2214\/AJR.05.0439","volume":"187","author":"T Franquet","year":"2006","unstructured":"Franquet T et al (2006) Thin-section CT findings in hematopoietic stem cell transplantation recipients with respiratory virus pneumonia. AJR Am J Roentgenol 187(4):1085\u20131090. https:\/\/doi.org\/10.2214\/AJR.05.0439","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"6769_CR62","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7326\/0003-4819-151-7-200910060-00142","volume":"151","author":"BJ Cowling","year":"2009","unstructured":"Cowling BJ et al (2009) Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med 151(7):437\u2013446. https:\/\/doi.org\/10.7326\/0003-4819-151-7-200910060-00142","journal-title":"Ann Intern Med"},{"key":"6769_CR63","doi-asserted-by":"publisher","first-page":"pCD006207","DOI":"10.1002\/14651858.CD006207.pub4","volume":"20117","author":"T Jefferson","year":"2011","unstructured":"Jefferson T et al (2011) Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 20117:pCD006207. https:\/\/doi.org\/10.1002\/14651858.CD006207.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"6769_CR64","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41591-020-0843-2","volume":"26","author":"NHL Leung","year":"2020","unstructured":"Leung NHL et al (2020) Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 26(5):676\u2013680. https:\/\/doi.org\/10.1038\/s41591-020-0843-2","journal-title":"Nat Med"},{"issue":"6577","key":"6769_CR65","doi-asserted-by":"publisher","first-page":"eabi9069","DOI":"10.1126\/science.abi9069","volume":"375","author":"J Abaluck","year":"2022","unstructured":"Abaluck J et al (2022) Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh. Science 375(6577):eabi9069. https:\/\/doi.org\/10.1126\/science.abi9069","journal-title":"Science"},{"issue":"10","key":"6769_CR66","doi-asserted-by":"publisher","first-page":"e0240287","DOI":"10.1371\/journal.pone.0240287","volume":"15","author":"M Alfelali","year":"2020","unstructured":"Alfelali M et al (2020) Facemask against viral respiratory infections among Hajj pilgrims: A challenging cluster-randomized trial. PLoS ONE 15(10):e0240287. https:\/\/doi.org\/10.1371\/journal.pone.0240287","journal-title":"PLoS ONE"},{"issue":"3","key":"6769_CR67","doi-asserted-by":"publisher","first-page":"335","DOI":"10.7326\/M20-6817","volume":"174","author":"H Bundgaard","year":"2021","unstructured":"Bundgaard H et al (2021) Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: A randomized controlled trial. Ann Intern Med 174(3):335\u2013343. https:\/\/doi.org\/10.7326\/M20-6817","journal-title":"Ann Intern Med"},{"issue":"10242","key":"6769_CR68","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/S0140-6736(20)31142-9","volume":"395","author":"DK Chu","year":"2020","unstructured":"Chu DK et al (2020) Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 395(10242):1973\u20131987. https:\/\/doi.org\/10.1016\/S0140-6736(20)31142-9","journal-title":"Lancet"},{"issue":"5","key":"6769_CR69","doi-asserted-by":"publisher","first-page":"e12582","DOI":"10.1002\/emp2.12582","volume":"2","author":"AP Collins","year":"2021","unstructured":"Collins AP et al (2021) N95 respirator and surgical mask effectiveness against respiratory viral illnesses in the healthcare setting: A systematic review and meta-analysis. J Am Coll Emerg Physicians Open 2(5):e12582. https:\/\/doi.org\/10.1002\/emp2.12582","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"9","key":"6769_CR70","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jama.2019.11645","volume":"322","author":"LJ Radonovich Jr","year":"2019","unstructured":"Radonovich LJ Jr. et al (2019) N95 respirators vs medical masks for preventing influenza among health care personnel: A randomized clinical trial. JAMA 322(9):824\u2013833. https:\/\/doi.org\/10.1001\/jama.2019.11645","journal-title":"JAMA"},{"key":"6769_CR71","doi-asserted-by":"publisher","unstructured":"Team RSVOI, Team RSVOI (2014) Contributing and terminating factors of a large RSV outbreak in an adult hematology and transplant unit. PLoS Curr 6. https:\/\/doi.org\/10.1371\/currents.outbreaks.3bc85b2a508d205ecc4a5534ecb1f9be","DOI":"10.1371\/currents.outbreaks.3bc85b2a508d205ecc4a5534ecb1f9be"},{"issue":"3","key":"6769_CR72","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1056\/NEJMc2406750","volume":"392","author":"VG Hall","year":"2025","unstructured":"Hall VG et al (2025) Influenza vaccination strategies in patients with hematologic cancer. N Engl J Med 392(3):306\u2013308. https:\/\/doi.org\/10.1056\/NEJMc2406750","journal-title":"N Engl J Med"},{"issue":"8","key":"6769_CR73","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/infdis\/jiab391","volume":"225","author":"J Linnik","year":"2022","unstructured":"Linnik J et al (2022) Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant patients. J Infect Dis 225(8):1482\u20131493. https:\/\/doi.org\/10.1093\/infdis\/jiab391","journal-title":"J Infect Dis"},{"issue":"5","key":"6769_CR74","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/cncr.30468","volume":"123","author":"B Keam","year":"2017","unstructured":"Keam B et al (2017) Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer 123(5):841\u2013848. https:\/\/doi.org\/10.1002\/cncr.30468","journal-title":"Cancer"},{"issue":"2","key":"6769_CR75","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/annonc\/mdr141","volume":"23","author":"B Rousseau","year":"2012","unstructured":"Rousseau B et al (2012) Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and\/or targeted therapy: the VACANCE study. Ann Oncol 23(2):450\u2013457. https:\/\/doi.org\/10.1093\/annonc\/mdr141","journal-title":"Ann Oncol"},{"issue":"2","key":"6769_CR76","doi-asserted-by":"publisher","first-page":"pCD008983","DOI":"10.1002\/14651858.CD008983.pub3","volume":"2","author":"R Bitterman","year":"2018","unstructured":"Bitterman R et al (2018) Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2(2):pCD008983. https:\/\/doi.org\/10.1002\/14651858.CD008983.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"10308","key":"6769_CR77","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","volume":"398","author":"PR Krause","year":"2021","unstructured":"Krause PR et al (2021) Considerations in boosting COVID-19 vaccine immune responses. Lancet 398(10308):1377\u20131380. https:\/\/doi.org\/10.1016\/S0140-6736(21)02046-8","journal-title":"Lancet"},{"issue":"7","key":"6769_CR78","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A et al (2023) Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 388(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2209604","journal-title":"N Engl J Med"},{"issue":"16","key":"6769_CR79","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE et al (2023) Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 388(16):1465\u20131477. https:\/\/doi.org\/10.1056\/NEJMoa2213836","journal-title":"N Engl J Med"},{"issue":"24","key":"6769_CR80","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson E et al (2023) Efficacy and safety of an mRNA-Based RSV pref vaccine in older adults. N Engl J Med 389(24):2233\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2307079","journal-title":"N Engl J Med"},{"issue":"23","key":"6769_CR81","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y et al (2021) Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 137(23):3165\u20133173. https:\/\/doi.org\/10.1182\/blood.2021011568","journal-title":"Blood"},{"issue":"9","key":"6769_CR82","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.2021012443","volume":"138","author":"P Ghione","year":"2021","unstructured":"Ghione P et al (2021) Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood 138(9):811\u2013814. https:\/\/doi.org\/10.1182\/blood.2021012443","journal-title":"Blood"},{"key":"6769_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020182","author":"MM Ruthrich","year":"2022","unstructured":"Ruthrich MM et al (2022) Cellular immune response after vaccination in patients with cancer-review on past and present experiences. Vaccines. https:\/\/doi.org\/10.3390\/vaccines10020182","journal-title":"Vaccines"},{"issue":"7-8","key":"6769_CR84","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1345\/aph.1A277","volume":"36","author":"JR Arrowood","year":"2002","unstructured":"Arrowood JR (2002) M.S. <>Hayney Immunization recommendations for adults with cancer. Ann Pharmacother 36 7-8 1219\u20131229 https:\/\/doi.org\/10.1345\/aph.1A277","journal-title":"Ann Pharmacother"},{"issue":"9","key":"6769_CR85","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jama.1992.03480090085032","volume":"267","author":"LJ Kaplan","year":"1992","unstructured":"Kaplan LJ et al (1992) Severe measles in immunocompromised patients. JAMA 267(9):1237\u20131241","journal-title":"JAMA"},{"issue":"6","key":"6769_CR86","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1586\/14760584.3.6.643","volume":"3","author":"R Belshe","year":"2004","unstructured":"Belshe R et al (2004) Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 3(6):643\u2013654. https:\/\/doi.org\/10.1586\/14760584.3.6.643","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"6769_CR87","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","volume":"29","author":"CT Rieger","year":"2018","unstructured":"Rieger CT et al (2018) Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO). Ann Oncol 29(6):1354\u20131365. https:\/\/doi.org\/10.1093\/annonc\/mdy117","journal-title":"Ann Oncol"},{"issue":"23","key":"6769_CR88","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ et al (2022) Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med 386(23):2188\u20132200. https:\/\/doi.org\/10.1056\/NEJMoa2116620","journal-title":"N Engl J Med"},{"issue":"1","key":"6769_CR89","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas D et al (2024) Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun 15(1):2254. https:\/\/doi.org\/10.1038\/s41467-024-46490-7","journal-title":"Nat Commun"},{"key":"6769_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00804-1","author":"G Haidar","year":"2025","unstructured":"Haidar G et al (2025) Efficacy and safety of Sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(24)00804-1","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"6769_CR91","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMc2404555","volume":"391","author":"P Schmidt","year":"2024","unstructured":"Schmidt P, Li Y, Popejoy M (2024) Immunobridging for Pemivibart, a monoclonal antibody for prevention of COVID-19. N Engl J Med 391(19):1860\u20131862. https:\/\/doi.org\/10.1056\/NEJMc2404555","journal-title":"N Engl J Med"},{"issue":"1","key":"6769_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v10i1.752","volume":"10","author":"D Planas","year":"2024","unstructured":"Planas D et al (2024) Escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP3.3 from approved monoclonal antibodies. Pathog Immun 10(1):1\u201311. https:\/\/doi.org\/10.20411\/pai.v10i1.752","journal-title":"Pathog Immun"},{"issue":"753","key":"6769_CR93","doi-asserted-by":"publisher","first-page":"eado2817","DOI":"10.1126\/scitranslmed.ado2817","volume":"16","author":"Y Cai","year":"2024","unstructured":"Cai Y et al (2024) AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults. Sci Transl Med 16(753):eado2817. https:\/\/doi.org\/10.1126\/scitranslmed.ado2817","journal-title":"Sci Transl Med"},{"key":"6769_CR94","unstructured":"European Respiratory Virus Surveillance Summary. 23.02.2025; Available from: https:\/\/erviss.org\/"},{"issue":"6","key":"6769_CR95","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H et al (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European myeloma network. Lancet Oncol 24(6):e255\u2013e269. https:\/\/doi.org\/10.1016\/S1470-2045(23)00159-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"6769_CR96","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N et al (2023) Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 13(1):116. https:\/\/doi.org\/10.1038\/s41408-023-00879-7","journal-title":"Blood Cancer J"},{"issue":"5","key":"6769_CR97","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1086\/422994","volume":"39","author":"AJ Peck","year":"2004","unstructured":"Peck AJ, Corey L, Boeckh M (2004) Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis 39(5):673\u2013680. https:\/\/doi.org\/10.1086\/422994","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6769_CR98","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.bmt.1701946","volume":"24","author":"T Aslan","year":"1999","unstructured":"Aslan T et al (1999) Patients with multiple myeloma May safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transpl 24(5):505\u2013509. https:\/\/doi.org\/10.1038\/sj.bmt.1701946","journal-title":"Bone Marrow Transpl"},{"key":"6769_CR99","doi-asserted-by":"publisher","first-page":"662211","DOI":"10.3389\/fonc.2021.662211","volume":"11","author":"K Wozniak","year":"2021","unstructured":"Wozniak K et al (2021) Chemotherapy during active SARS-CoV2 infection: A case report and review of the literature. Front Oncol 11:662211. https:\/\/doi.org\/10.3389\/fonc.2021.662211","journal-title":"Front Oncol"},{"issue":"21","key":"6769_CR100","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1002\/cam4.3435","volume":"9","author":"L Hempel","year":"2020","unstructured":"Hempel L, et, al (2020) SARS-CoV-2 infections in cancer outpatients-Most infected patients are asymptomatic carriers without impact on chemotherapy. Cancer Med 9(21):8020\u20138028. https:\/\/doi.org\/10.1002\/cam4.3435","journal-title":"Cancer Med"},{"issue":"18","key":"6769_CR101","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1002\/cncr.27447","volume":"118","author":"RF Chemaly","year":"2012","unstructured":"Chemaly RF et al (2012) A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer 118(18):4627\u20134633. https:\/\/doi.org\/10.1002\/cncr.27447","journal-title":"Cancer"},{"issue":"4","key":"6769_CR102","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL et al (2022) Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 386(4):305\u2013315. https:\/\/doi.org\/10.1056\/NEJMoa2116846","journal-title":"N Engl J Med"},{"issue":"6","key":"6769_CR103","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A et al (2022) Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 386(6):509\u2013520. https:\/\/doi.org\/10.1056\/NEJMoa2116044","journal-title":"N Engl J Med"},{"issue":"15","key":"6769_CR104","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J et al (2022) Oral nirmatrelvir for High-Risk, nonhospitalized adults with Covid-19. N Engl J Med 386(15):1397\u20131408. https:\/\/doi.org\/10.1056\/NEJMoa2118542","journal-title":"N Engl J Med"},{"issue":"6","key":"6769_CR105","doi-asserted-by":"publisher","first-page":"CD000247","DOI":"10.1002\/14651858.CD000247.pub3","volume":"2013","author":"T Kenealy","year":"2013","unstructured":"Kenealy T, Arroll B (2013) Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev 2013(6):CD000247. https:\/\/doi.org\/10.1002\/14651858.CD000247.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6769_CR106","first-page":"1","volume":"60","author":"AE Fiore","year":"2011","unstructured":"Fiore AE et al (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 60(1):1\u201324","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"6769_CR107","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1182\/blood-2009-11-255455","volume":"115","author":"C Casper","year":"2010","unstructured":"Casper C, Englund J, Boeckh M (2010) How i treat influenza in patients with hematologic malignancies. Blood 115(7):1331\u20131342. https:\/\/doi.org\/10.1182\/blood-2009-11-255455","journal-title":"Blood"},{"issue":"3","key":"6769_CR108","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/tid.12054","volume":"15","author":"D Engelhard","year":"2013","unstructured":"Engelhard D et al (2013) European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 15(3):219\u2013232. https:\/\/doi.org\/10.1111\/tid.12054","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"6769_CR109","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/sj.bmt.1703343","volume":"29","author":"AA Johny","year":"2002","unstructured":"Johny AA et al (2002) The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transpl 29(2):113\u2013115. https:\/\/doi.org\/10.1038\/sj.bmt.1703343","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"6769_CR110","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1086\/512374","volume":"44","author":"RF Chemaly","year":"2007","unstructured":"Chemaly RF et al (2007) Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 44(7):964\u2013967. https:\/\/doi.org\/10.1086\/512374","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6769_CR111","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","volume":"20","author":"MG Ison","year":"2020","unstructured":"Ison MG et al (2020) Early treatment with Baloxavir Marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 20(10):1204\u20131214. https:\/\/doi.org\/10.1016\/S1473-3099(20)30004-9","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"6769_CR112","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1086\/518985","volume":"45","author":"D Vu","year":"2007","unstructured":"Vu D et al (2007) Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 45(2):187\u2013193. https:\/\/doi.org\/10.1086\/518985","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6769_CR113","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.285.6.748","volume":"285","author":"R Welliver","year":"2001","unstructured":"Welliver R et al (2001) Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285(6):748\u2013754. https:\/\/doi.org\/10.1001\/jama.285.6.748","journal-title":"JAMA"},{"issue":"10454","key":"6769_CR114","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0140-6736(24)01357-6","volume":"404","author":"Y Zhao","year":"2024","unstructured":"Zhao Y et al (2024) Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet 404(10454):764\u2013772. https:\/\/doi.org\/10.1016\/S0140-6736(24)01357-6","journal-title":"Lancet"},{"issue":"2","key":"6769_CR115","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/tid.12194","volume":"16","author":"JR Marcelin","year":"2014","unstructured":"Marcelin JR et al (2014) Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 16(2):242\u2013250. https:\/\/doi.org\/10.1111\/tid.12194","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"6769_CR116","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1182\/blood-2003-05-1425","volume":"103","author":"EJ Anaissie","year":"2004","unstructured":"Anaissie EJ et al (2004) The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood 103(5):1611\u20131617. https:\/\/doi.org\/10.1182\/blood-2003-05-1425","journal-title":"Blood"},{"issue":"1","key":"6769_CR117","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1399-3062.2012.00764.x","volume":"15","author":"ET Mendes","year":"2013","unstructured":"Mendes ET et al (2013) An outbreak of respiratory syncytial virus infection in hematopoietic stem cell transplantation outpatients: good outcome without specific antiviral treatment. Transpl Infect Dis 15(1):42\u201348. https:\/\/doi.org\/10.1111\/j.1399-3062.2012.00764.x","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"6769_CR118","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cmi.2023.04.021","volume":"29","author":"K Manothummetha","year":"2023","unstructured":"Manothummetha K et al (2023) Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and Haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect 29(10):1272\u20131279. https:\/\/doi.org\/10.1016\/j.cmi.2023.04.021","journal-title":"Clin Microbiol Infect"},{"issue":"4276","key":"6769_CR119","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.401547","volume":"195","author":"L Kilham","year":"1977","unstructured":"Kilham L, Ferm VH (1977) Congenital anomalies induced in hamster embryos with ribavirin. Science 195(4276):413\u2013414. https:\/\/doi.org\/10.1126\/science.401547","journal-title":"Science"},{"issue":"4","key":"6769_CR120","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/tid.12092","volume":"15","author":"S Gueller","year":"2013","unstructured":"Gueller S et al (2013) Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 15(4):435\u2013440. https:\/\/doi.org\/10.1111\/tid.12092","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"6769_CR121","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jinf.2019.04.004","volume":"78","author":"K Balassa","year":"2019","unstructured":"Balassa K et al (2019) Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation. J Infect 78(6):461\u2013467. https:\/\/doi.org\/10.1016\/j.jinf.2019.04.004","journal-title":"J Infect"},{"issue":"10","key":"6769_CR122","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciy760","volume":"68","author":"F Foolad","year":"2019","unstructured":"Foolad F et al (2019) Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis 68(10):1641\u20131649. https:\/\/doi.org\/10.1093\/cid\/ciy760","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6769_CR123","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1086\/525263","volume":"46","author":"N Khanna","year":"2008","unstructured":"Khanna N et al (2008) Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 46(3):402\u2013412. https:\/\/doi.org\/10.1086\/525263","journal-title":"Clin Infect Dis"},{"key":"6769_CR124","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12657","author":"AR Falsey","year":"2017","unstructured":"Falsey AR et al (2017) Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis. https:\/\/doi.org\/10.1111\/tid.12657","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"6769_CR125","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/10428194.2018.1468896","volume":"60","author":"N Permpalung","year":"2019","unstructured":"Permpalung N et al (2019) Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving Palivizumab. Leuk Lymphoma 60(1):85\u201391. https:\/\/doi.org\/10.1080\/10428194.2018.1468896","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"6769_CR126","doi-asserted-by":"publisher","first-page":"e0271756","DOI":"10.1371\/journal.pone.0271756","volume":"17","author":"J Tabatabai","year":"2022","unstructured":"Tabatabai J et al (2022) Parainfluenza virus infections in patients with hematological malignancies or stem cell transplantation: analysis of clinical characteristics, nosocomial transmission and viral shedding. PLoS ONE 17(7):e0271756. https:\/\/doi.org\/10.1371\/journal.pone.0271756","journal-title":"PLoS ONE"},{"issue":"2","key":"6769_CR127","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41409-020-01022-x","volume":"56","author":"M Stamouli","year":"2021","unstructured":"Stamouli M et al (2021) Oral ribavirin is a highly effective treatment for lower respiratory tract infections due to respiratory syncytial virus or parainfluenza after allogeneic stem cell transplantation. Bone Marrow Transpl 56(2):511\u2013513. https:\/\/doi.org\/10.1038\/s41409-020-01022-x","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"6769_CR128","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.bmt.1703798","volume":"31","author":"P Ljungman","year":"2003","unstructured":"Ljungman P et al (2003) Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the infectious diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transpl 31(6):481\u2013486. https:\/\/doi.org\/10.1038\/sj.bmt.1703798","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"6769_CR129","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkab259","volume":"76","author":"A Stern","year":"2021","unstructured":"Stern A et al (2021) Safety and efficacy of intravenously administered Cidofovir in adult Haematopoietic cell transplant recipients: a retrospective multicentre cohort study. J Antimicrob Chemother 76(11):3020\u20133028. https:\/\/doi.org\/10.1093\/jac\/dkab259","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"6769_CR130","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood.V84.5.1689.1689","volume":"84","author":"R Hromas","year":"1994","unstructured":"Hromas R et al (1994) Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 84(5):1689\u20131690","journal-title":"Blood"},{"issue":"4","key":"6769_CR131","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/CJI.0000000000000034","volume":"37","author":"R Geyeregger","year":"2014","unstructured":"Geyeregger R et al (2014) First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J Immunother 37(4):245\u2013249. https:\/\/doi.org\/10.1097\/CJI.0000000000000034","journal-title":"J Immunother"},{"issue":"1","key":"6769_CR132","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/infdis\/jiad268","volume":"229","author":"JL Pinana","year":"2024","unstructured":"Pinana JL et al (2024) Upper and\/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation. J Infect Dis 229(1):83\u201394. https:\/\/doi.org\/10.1093\/infdis\/jiad268","journal-title":"J Infect Dis"},{"key":"6769_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060634","author":"I Nachtigall","year":"2024","unstructured":"Nachtigall I et al (2024) Retrospective, observational analysis on the impact of SARS-CoV-2 variant Omicron in hospitalized immunocompromised patients in a German hospital network-the VISAGE study. Vaccines. https:\/\/doi.org\/10.3390\/vaccines12060634","journal-title":"Vaccines"},{"issue":"6","key":"6769_CR134","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/jac\/dkad105","volume":"78","author":"TF Aiello","year":"2023","unstructured":"Aiello TF et al (2023) Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals. J Antimicrob Chemother 78(6):1454\u20131459. https:\/\/doi.org\/10.1093\/jac\/dkad105","journal-title":"J Antimicrob Chemother"},{"key":"6769_CR135","doi-asserted-by":"publisher","first-page":"101939","DOI":"10.1016\/j.eclinm.2023.101939","volume":"58","author":"J Salmanton-Garcia","year":"2023","unstructured":"Salmanton-Garcia J et al (2023) Nirmatrelvir\/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. EClinicalMedicine 58:101939. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101939","journal-title":"EClinicalMedicine"},{"issue":"9","key":"6769_CR136","doi-asserted-by":"publisher","first-page":"e2335077","DOI":"10.1001\/jamanetworkopen.2023.35077","volume":"6","author":"DY Lin","year":"2023","unstructured":"Lin DY et al (2023) Nirmatrelvir or molnupiravir use and severe outcomes from Omicron infections. JAMA Netw Open 6(9):e2335077. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.35077","journal-title":"JAMA Netw Open"},{"issue":"4","key":"6769_CR137","doi-asserted-by":"publisher","first-page":"106952","DOI":"10.1016\/j.ijantimicag.2023.106952","volume":"62","author":"J Salmanton-Garcia","year":"2023","unstructured":"Salmanton-Garcia J et al (2023) Molnupiravir compared to nirmatrelvir\/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry. Int J Antimicrob Agents 62(4):106952. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106952","journal-title":"Int J Antimicrob Agents"},{"key":"6769_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225530","author":"C Cattaneo","year":"2022","unstructured":"Cattaneo C et al (2022) Simultaneous onset of haematological malignancy and COVID: an epicovideha survey. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14225530","journal-title":"Cancers (Basel)"},{"issue":"13","key":"6769_CR139","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","volume":"390","author":"J Hammond","year":"2024","unstructured":"Hammond J et al (2024) Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. N Engl J Med 390(13):1186\u20131195. https:\/\/doi.org\/10.1056\/NEJMoa2309003","journal-title":"N Engl J Med"},{"issue":"5","key":"6769_CR140","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/hon.3206","volume":"41","author":"Z Pasquini","year":"2023","unstructured":"Pasquini Z et al (2023) Dual combined antiviral treatment with Remdesivir and nirmatrelvir\/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection. Hematol Oncol 41(5):904\u2013911. https:\/\/doi.org\/10.1002\/hon.3206","journal-title":"Hematol Oncol"},{"key":"6769_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12091460","author":"BM Longo","year":"2023","unstructured":"Longo BM et al (2023) Sequential or combination treatments as rescue therapies in immunocompromised patients with persistent SARS-CoV-2 infection in the Omicron era: a case series. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics12091460","journal-title":"Antibiotics"},{"issue":"3","key":"6769_CR142","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s15010-023-02125-5","volume":"52","author":"HM Orth","year":"2024","unstructured":"Orth HM et al (2024) Early combination therapy of COVID-19 in high-risk patients. Infection 52(3):877\u2013889. https:\/\/doi.org\/10.1007\/s15010-023-02125-5","journal-title":"Infection"},{"issue":"2","key":"6769_CR143","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cid\/ciad181","volume":"77","author":"M Mikulska","year":"2023","unstructured":"Mikulska M et al (2023) Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis 77(2):280\u2013286. https:\/\/doi.org\/10.1093\/cid\/ciad181","journal-title":"Clin Infect Dis"},{"key":"6769_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00221-X","author":"E Weinstein","year":"2025","unstructured":"Weinstein E et al (2025) Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(25)00221-X","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"6769_CR145","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHOST Consortium","year":"2021","unstructured":"Consortium WHOST et al (2021) Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 384(6):497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"issue":"19","key":"6769_CR146","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH et al (2020) Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med 383(19):1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"issue":"2","key":"6769_CR147","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","volume":"22","author":"F Ader","year":"2022","unstructured":"Ader F et al (2022) Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 22(2):209\u2013221. https:\/\/doi.org\/10.1016\/S1473-3099(21)00485-0","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"6769_CR148","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1093\/cid\/ciab1035","volume":"75","author":"BT Garibaldi","year":"2022","unstructured":"Garibaldi BT et al (2022) Real-World effectiveness of Remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): A Retrospective, multicenter comparative effectiveness study. Clin Infect Dis 75(1):e516\u2013e524. https:\/\/doi.org\/10.1093\/cid\/ciab1035","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"6769_CR149","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1093\/cid\/ciae510","volume":"79","author":"E Mozaffari","year":"2024","unstructured":"Mozaffari E et al (2024) Remdesivir-Associated survival outcomes among immunocompromised patients hospitalized for COVID-19: Real-world evidence from the Omicron-Dominant era. Clin Infect Dis 79(Suppl 4):S149\u2013S159. https:\/\/doi.org\/10.1093\/cid\/ciae510","journal-title":"Clin Infect Dis"},{"issue":"8","key":"6769_CR150","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RC Group","year":"2021","unstructured":"Group RC et al (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"issue":"9","key":"6769_CR151","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC et al (2021) Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med 384(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994","journal-title":"N Engl J Med"},{"issue":"5","key":"6769_CR152","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"PO Guimaraes","year":"2021","unstructured":"Guimaraes PO et al (2021) Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 385(5):406\u2013415. https:\/\/doi.org\/10.1056\/NEJMoa2101643","journal-title":"N Engl J Med"},{"issue":"7","key":"6769_CR153","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich VA et al (2021) A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 384(7):619\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2031304","journal-title":"N Engl J Med"},{"issue":"10289","key":"6769_CR154","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"RC Group","year":"2021","unstructured":"Group RC (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397(10289):2049\u20132059. https:\/\/doi.org\/10.1016\/S0140-6736(21)00897-7","journal-title":"Lancet"},{"issue":"1","key":"6769_CR155","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s43018-022-00503-w","volume":"4","author":"CM Denkinger","year":"2023","unstructured":"Denkinger CM et al (2023) Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer 4(1):96\u2013107. https:\/\/doi.org\/10.1038\/s43018-022-00503-w","journal-title":"Nat Cancer"},{"issue":"5","key":"6769_CR156","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","volume":"39","author":"HK Siddiqi","year":"2020","unstructured":"Siddiqi HK, Mehra MR (2020) COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 39(5):405\u2013407. https:\/\/doi.org\/10.1016\/j.healun.2020.03.012","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"6769_CR157","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmi.2023.12.028","volume":"30","author":"DA Sweeney","year":"2024","unstructured":"Sweeney DA et al (2024) Choosing Immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence. Clin Microbiol Infect 30(5):611\u2013618. https:\/\/doi.org\/10.1016\/j.cmi.2023.12.028","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"6769_CR158","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S2213-2600(25)00081-5","volume":"13","author":"DA Sweeney","year":"2025","unstructured":"Sweeney DA, Kalil AC (2025) Guidelines without borders: the case for JAK inhibitors as the first-line immunomodulator COVID-19 treatment. Lancet Respir Med 13(6):478\u2013480. https:\/\/doi.org\/10.1016\/S2213-2600(25)00081-5","journal-title":"Lancet Respir Med"},{"issue":"6","key":"6769_CR159","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S2213-2600(25)00055-4","volume":"13","author":"A Amstutz","year":"2025","unstructured":"Amstutz A et al (2025) Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials. Lancet Respir Med 13(6):530\u2013544. https:\/\/doi.org\/10.1016\/S2213-2600(25)00055-4","journal-title":"Lancet Respir Med"},{"issue":"12","key":"6769_CR160","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC et al (2021) Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9(12):1407\u20131418. https:\/\/doi.org\/10.1016\/S2213-2600(21)00331-3","journal-title":"Lancet Respir Med"},{"key":"6769_CR161","unstructured":"Therapeutic Management of Hospitalized Adults With COVID-19. (2024) February 29,2024; Available from: https:\/\/adsp.nm.org\/uploads\/1\/4\/3\/0\/143064172\/nih_hosp_adult_guideline.pdf"},{"issue":"4","key":"6769_CR162","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"EW Ely","year":"2022","unstructured":"Ely EW et al (2022) Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med 10(4):327\u2013336. https:\/\/doi.org\/10.1016\/S2213-2600(22)00006-6","journal-title":"Lancet Respir Med"},{"issue":"9","key":"6769_CR163","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(22)00088-1","volume":"10","author":"CR Wolfe","year":"2022","unstructured":"Wolfe CR et al (2022) Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med 10(9):888\u2013899. https:\/\/doi.org\/10.1016\/S2213-2600(22)00088-1","journal-title":"Lancet Respir Med"},{"issue":"10285","key":"6769_CR164","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RC Group","year":"2021","unstructured":"Group RC (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397(10285):1637\u20131645. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"6769_CR165","doi-asserted-by":"publisher","unstructured":"group C-C (2021) Effect of Anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 9(3):295\u2013304. https:\/\/doi.org\/10.1016\/S2213-2600(20)30556-7","DOI":"10.1016\/S2213-2600(20)30556-7"},{"issue":"10","key":"6769_CR166","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E et al (2021) Early treatment of COVID-19 with Anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 27(10):1752\u20131760. https:\/\/doi.org\/10.1038\/s41591-021-01499-z","journal-title":"Nat Med"},{"issue":"8","key":"6769_CR167","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.3324\/haematol.2023.284678","volume":"109","author":"TF Aiello","year":"2024","unstructured":"Aiello TF et al (2024) Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry. Haematologica 109(8):2693\u20132700. https:\/\/doi.org\/10.3324\/haematol.2023.284678","journal-title":"Haematologica"},{"key":"6769_CR168","unstructured":"Stefan Kluge UJ, Gereon Sch\u00e4lte CD, Spinner, Jakob J, Malin et al S3-Leitlinie - Empfehlungen zur Therapie von Patienten mit COVID-19. 2024 23.09.2024; Available from: https:\/\/register.awmf.org\/assets\/guidelines\/113-001l_S3_Empfehlungen-zur-Therapie-von-Patienten-mit-COVID-19_2024-09.pdf"},{"issue":"10291","key":"6769_CR169","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","volume":"397","author":"RD Lopes","year":"2021","unstructured":"Lopes RD et al (2021) Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397(10291):2253\u20132263. https:\/\/doi.org\/10.1016\/S0140-6736(21)01203-4","journal-title":"Lancet"},{"issue":"16","key":"6769_CR170","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2020.08.041","volume":"76","author":"GN Nadkarni","year":"2020","unstructured":"Nadkarni GN et al (2020) Anticoagulation, Bleeding, Mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 76(16):1815\u20131826. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.041","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6769_CR171","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamainternmed.2023.0456","volume":"183","author":"V Labbe","year":"2023","unstructured":"Labbe V et al (2023) Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and therapeutic anticoagulation in patients with hypoxemic COVID-19 pneumonia: the ANTICOVID randomized clinical trial. JAMA Intern Med 183(6):520\u2013531. https:\/\/doi.org\/10.1001\/jamainternmed.2023.0456","journal-title":"JAMA Intern Med"},{"issue":"16","key":"6769_CR172","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"I Investigators","year":"2021","unstructured":"Investigators I et al (2021) Effect of Intermediate-Dose vs Standard-Dose prophylactic anticoagulation on thrombotic Events, extracorporeal membrane oxygenation Treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 325(16):1620\u20131630. https:\/\/doi.org\/10.1001\/jama.2021.4152","journal-title":"JAMA"},{"key":"6769_CR173","doi-asserted-by":"publisher","first-page":"n2400","DOI":"10.1136\/bmj.n2400","volume":"375","author":"M Sholzberg","year":"2021","unstructured":"Sholzberg M et al (2021) Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375:n2400. https:\/\/doi.org\/10.1136\/bmj.n2400","journal-title":"BMJ"},{"issue":"9","key":"6769_CR174","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","volume":"385","author":"A Investigators","year":"2021","unstructured":"Investigators A et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 385(9):790\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa2105911","journal-title":"N Engl J Med"},{"issue":"9","key":"6769_CR175","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1111\/jth.15450","volume":"19","author":"US Perepu","year":"2021","unstructured":"Perepu US et al (2021) Standard prophylactic versus intermediate dose Enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 19(9):2225\u20132234. https:\/\/doi.org\/10.1111\/jth.15450","journal-title":"J Thromb Haemost"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06769-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06769-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06769-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:37Z","timestamp":1771398217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06769-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":175,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6769"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06769-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NG reports honoraria from Abbvie, AstraZeneca, Gilead, GSK, Hexal, Janssen, MSD, Oncopeptides, Pfizer, Sanofi, Takeda, and was consultant to AstraZeneca, BMS, MSD, Oncopeptides, Pfizer, Sanofi, Takeda. OAC reports research grants or contracts from iMi, iHi, DFG, BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis, consulting fees from Abbvie, AiCuris, Basilea, Biocon, Cidara, Elion Therapeutics, Gilead, GSK, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, Melinta, MSG-ERC, Mundipharma, Noxxon, Octapharma, Pardes, Partner Therapeutics, Pfizer, PSI, Scynexis, Seres, Seqirus, honoraria from Abbott, Abbvie, Akademie f\u00fcr Infektionsmedizin, Al-Jazeera Pharmaceuticals\/Hikma, amedes, AstraZeneca, Deutscher \u00c4rzteverlag, Gilead, GSK, Grupo Biotoscana\/United Medical\/Knight, Ipsen Pharma, Medscape\/WebMD, MedUpdate, MSD, Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi, streamedup!, Touch Independent, Vitis, payment for expert testimony from Cidara, participation on data safety monitoring or advisory boards from AstraZeneca, Boston Strategic Partners, Cidara, IQVIA, Janssen, MedPace, Melinta, PSI, Pulmocide, Shionogi, The Prime Meridian Group, Vedanta Biosciences. BEOJ reports honoraria from AstraZeneca, Gilead, Pfizer, GSK, ViiV, Janssen, Bristol Myers Squibb, Fresenius Medical Care, Falk Foundation, MSD and was consultant to GSK, ViiV, Gilead, MSD, AstraZeneca, Theratechnologies. MBM received honoraria and travel grants from AbbVie, AstraZeneca, Gilead Sciences, Novavax, Pfizer, ViiV Healthcare. SCM reports research grants form DZIF and University of Cologne and has received honoraria as a speaker by Pfizer. CR reports honoraria and has served on advisory boards from Abbvie, AstraZeneca, BeiGene, Bristol Myers Squibb, CSL Sequirius, Gilead, GSK, Johnson & Johnson, Merck Sharp & Dohme, Oncopeptides, Pfizer, Roche, and Sanofi. KS reports honoraria from Abbvie, Alexa, Jazz Pharmaceuticals, Pfizer, Sanofi, Stemline, Takeda, Sobi, Leo Pharma, Servier, Bristol Myers Squibb, MSD, Gilead, AstraZeneca, SoBi. MH reports honoraria from Amgen, Beigene, Gilead, Janssen, Sanofi, and Menarini, and served on advisory boards of Amgen, Beigene, BMS, Gilead, Janssen, Menarini, Merck, Oncopeptides, and Sanofi. PS reports honoraria and\/or consulting fees from Alexion, AOP Orphan, Blueprint Medicines, Bristol Myers Squibb, Sanofi, Incyte, Merck Serono, MSD, Novartis, Pfizer, Roche, Swedish Orphan Biovitrum, and GSK. DT has received research grants from Gilead, honoraria from and served as a consultant to AbbVie, BioNTech, Gilead, iQone, Jazz, Mikrogen, MSD, Noscendo, Octapharma, Pfizer, Tillotts, and Takeda, honoraria from AstraZeneca, F2G, Janssen, Novartis, and Sanofi, and travel grants from AbbVie, Astellas, Celgene, Gilead, Jazz, Medac, MSD, and Tillotts. SV: MSD, SymBio, Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}